The European Pain Management Markets: Analysis and Strategic Recommendations

1
The European Pain Management Markets Analysis
and Strategic Recommendations

• Christian Downton
• Analyst Briefing
• 6 August 2002
• London Office

2
Introduction

• Pain management
• Is the treatment of a patient-subjective
  experience
• Uses a variety of drug-classes
• Was previously experiencing saturation
• Is gaining more focus from authorities,
  physicians and patients

3
Pain Management segmentation

• This report examines the segments
• Anti-migraine drugs
• Opioids
• NSAIDs

4
Countries under study

• Wide variations in approaches to pain management
• Wide variations in segment revenue sizes
• Wide variations in key players market shares

5
Key factors
Model for other country markets
Generic competition and mature markets
Reimbursement restrictions
Conservative GPs and Aut idem
Quiet Opioid market and reimbursement
Opiophobia and national loyalty
Opiophobia and self-prescription
6
Novartis Phase IV TARGET study released
Bextra and Novartis coxib launched
Entry of generic sumatriptan likely
Arcoxia, Dynastat, Transtec launched
Durogesic success
Vioxx and Celebrex launched
7
Anti-migraine market

• Several country markets have growth potential
• Patent expiry of Imigran (sumatriptan) will
  affect key markets
• ForecastCAGR 7.7

8
Opioid market

• High price of patch and sustained-release
  products driving market
• Opiophobia still holding back sales in many
  countries
• ForecastCAGR 12.8

9
NSAID market

• High price of COX-2 inhibitors driving sales
• Reimbursement problems and side-effect issues
  restricting growth

10
Take-home comments

• Market worth 2.7 billion
• High level of growth forecast
• Pain Management of increasing importance for
  patient care
• Trend for innovative products, particularly in
  drug delivery
• Many products expanding indications

11
Please ask any questions you may have

• Thank you